Video Series

A panelist discusses how continuous glucose monitoring (CGM) technology can help overcome therapeutic inertia and key barriers to glycemic control in type 2 diabetes (T2D) patients by providing real-time data that enables earlier interventions, supports treatment optimization, and helps managed care organizations justify broader CGM adoption for newly diagnosed patients.

A panelist discusses how the multicenter ferric carboxymaltose trial employed a prospective design to evaluate iron supplementation's impact on heart failure outcomes, strategically selecting hospitalization reduction as the primary end point due to its clinical relevance and statistical power considerations.

Paul Feuerstadt, MD, FACG, AGAF, discusses how the management of recurrent Clostridioides difficile infections is evolving toward more targeted approaches, including microbiome-based therapies like fecal microbiota transplantation, newer antibiotics such as fidaxomicin, and emerging preventive strategies focusing on microbiome restoration and preservation.

Panelists discuss how alopecia areata (AA) is a chronic autoimmune disease characterized by inflammation that attacks hair follicles, leading to hair loss and varying disease progression.

A panelist discusses how the FINEARTS-HF trial employed rigorous potassium-monitoring protocols and predefined hyperkalemia thresholds to evaluate finerenone's safety profile in patients with heart failure (HF), revealing important associations between baseline characteristics and hyperkalemia risk while demonstrating the drug's complex effects on potassium homeostasis.

A panelist discusses how glucagon-like peptide-1 receptor (GLP-1) agonists' cardioprotective effects likely stem from multiple physiological mechanisms, including reduced inflammation, improved glucose metabolism, enhanced endothelial function, and potential antiatherosclerotic properties that collectively lower the risk of cardiac events.

The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut bacteria to restore microbiome diversity, distinguishing itself from traditional antibiotics in preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment.

The panelist discusses Rebyota, a treatment approved by the FDA for preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment for recurrent C difficile infections.

The panelist discusses how Rebyota is an FDA-approved microbiome therapeutic that delivers standardized, purified intestinal microbiota through enema administration to restore gut microbial diversity and prevent recurrent Clostridioides difficile infection, differing from conventional fecal microbiota transplantation (FMT) in its regulatory status, standardized manufacturing process, and enhanced safety profile due to extensive screening and purification of donor material.

The panelist discusses how fecal microbiota transplantation (FMT) involves transferring stool from healthy donors to restore gut microbiota in patients with recurrent Clostridioides difficile infection, though safety concerns include potential pathogen transmission and careful donor screening requirements, while OpenBiome’s standardized frozen FMT preparations have helped advance accessibility but should be used according to current FDA guidance for investigational use.

An analysis of challenges and strategies for integrating HER2-directed therapies into decision-making for NSCLC, with a focus on timely updates, collaborative efforts among stakeholders, and balancing equitable access with cost management.

An overview of challenges in transitioning from IV to oral medications and guidance on identifying NSCLC patient populations most likely to benefit from HER2-directed therapies through informed patient selection strategies.

A review of recent clinical trial results for emerging HER2-directed therapies, including SOHO-01, inetetamab/pyrotinib, and BEAMION Lung-01, and their potential impact on the future treatment landscape for HER2-positive NSCLC.

An exploration of emerging strategies to overcome resistance to HER2-directed therapies based on ongoing research advancements.

Dr Heymach real-world outcomes versus clinical trials for HER2-positive NSCLC and the management of common adverse events associated with HER2-directed therapies.

Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors such as recent antibiotic use, hospitalization, or older age, and how empiric treatment should be initiated while awaiting test results if there is high clinical suspension.

The panelist discusses how antibiotics are paradoxically both the primary treatment for Clostridioides difficile infections and a major risk factor for recurrence since they disrupt the protective gut microbiome, which led to the development of alternative therapies like fecal microbiota transplantation to restore microbial balance and prevent reinfection.

Amit Saxena, MD, discusses how personalized treatment decisions for lupus nephritis require careful consideration of patient characteristics, multidisciplinary coordination, and emerging guidelines, while acknowledging both the opportunities and challenges that lie ahead in clinical practice.

Amit Saxena, MD, discusses how evidence-based guidelines from ACR and KDIGO have evolved to shape lupus nephritis treatment approaches, emphasizing their critical role in standardizing patient care and incorporating recent advances like new therapeutic options and refined diagnostic criteria.

Toby Maher, MD, PhD, discusses how delays in treatment for idiopathic pulmonary fibrosis (IPF) can significantly worsen patient outcomes and accelerate disease progression, underscoring the critical need for timely intervention.

Toby Maher, MD, PhD, discusses the various barriers that frequently hinder patients with idiopathic pulmonary fibrosis (IPF) from receiving appropriate treatment and shares effective strategies he has implemented to overcome these challenges.

Panelists conclude by highlighting key takeaways in the management of NSCLC.

Panelists discuss how real-world evidence plays a crucial role in shaping both clinical decision-making and coverage policies for HER2-directed therapies in NSCLC, while exploring collaborative strategies between payers, providers, and manufacturers to balance equitable access with cost management.

Panelists discuss how health care providers and payers can collaborate more effectively to optimize lupus nephritis care.

Toby Maher, MD, PhD, discusses how common signs and symptoms of idiopathic pulmonary fibrosis (IPF) at diagnosis can indicate disease progression, while also identifying key risk factors associated with IPF and emphasizing the importance of modifying certain lifestyle factors to help prevent the disease.

Toby Maher, MD, PhD, discusses how comorbidities complicate the diagnosis and management of idiopathic pulmonary fibrosis (IPF) and influence treatment decisions, highlighting the need for a comprehensive approach in patient care.

Toby Maher, MD, PhD, discusses how idiopathic pulmonary fibrosis (IPF) is diagnosed through specific imaging and tests, with an average diagnosis time that can delay effective treatment, emphasizing that early diagnosis is crucial for reducing disease severity and expanding available treatment options.

Panelists discuss how unmet needs in type 2 inflammatory diseases require further research, including developing more personalized treatment approaches, identifying novel biomarkers for better disease phenotyping, improving long-term disease control strategies, and addressing the psychosocial impacts of chronic inflammatory conditions to enhance patients’ overall quality of life and outcomes.

The panel of experts concludes by exploring the implementation of cardiometabolic risk management learnings and the utilization of telehealth in clinical practice.

Panelists discuss how payer perspectives and access challenges impact the utilization of HER2-directed therapies in NSCLC, examining barriers to treatment initiation and persistence, aligning provider and payer priorities in outcome assessment, the role of real-world evidence in decision-making and policy formation, and strategies for collaborative efforts between stakeholders to balance equitable access with cost management.